Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Effectiveness of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use: Results from a 12-week Open-label Extension Phase.

Time Course of Effectiveness of Two Rimegepant Dosing Regimens for the Prevention of Episodic Migraine